Related Experiment Video

Updated: Aug 21, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2

Pedro Jose Real1, Yeyu Cao, Renxiao Wang

  • 1Unidad de Genetica Molecular and Servicio de Oncologia Medica, Hospital Universitario Marques de Valdecilla, Servicio Cantabro de Salud, Santander, Spain.

Cancer Research
|November 3, 2004
PubMed

Insights

A novel Bcl-2 inhibitor, YC137, selectively induces apoptosis in cancer cells overexpressing Bcl-2, sparing normal cells. Resistance mechanisms involve reduced Bcl-2 and HER2 expression, offering insights into cancer therapy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Proteins of the B-cell lymphoma 2 (Bcl-2) family regulate apoptosis.
  • Overexpression of Bcl-2 family members, like Bcl-2 and Bcl-x(L), is common in cancer and linked to chemoresistance.
  • Targeting Bcl-2 is a promising strategy for cancer therapy.

Purpose of the Study:

  • To design and synthesize a novel small molecule inhibitor of Bcl-2, named YC137.
  • To investigate the efficacy and selectivity of YC137 in inducing apoptosis in cancer cells.
  • To elucidate the mechanisms of resistance to YC137 and its relationship with signaling pathways.

Main Methods:

  • In vitro synthesis and characterization of YC137.
  • Assays to evaluate YC137's inhibition of Bcl-2 and Bid BH3 peptide interaction.
  • Apoptosis induction studies in various cancer cell lines and normal primary cells.
  • Generation and analysis of YC137-resistant cancer cell lines.
  • Investigation of signaling pathways including Signal Transducer and Activator of Transcription-3 (Stat3) and Human Epidermal Growth Factor Receptor-2 (HER2).

Main Results:

  • YC137 effectively inhibits Bcl-2's antiapoptotic activity by disrupting the Bcl-2-Bid BH3 peptide interaction.
  • YC137 selectively induces apoptosis in hematopoietic progenitors and breast cancer cells overexpressing Bcl-2, while sparing normal cells.
  • Analysis of YC137-resistant cells revealed decreased Bcl-2 expression, correlated with reduced Stat3 activation and HER2 expression.
  • HER2 blockade led to Stat3 down-regulation, reduced Bcl-2 levels, and YC137 resistance, suggesting a novel HER2-Stat3-Bcl-2 axis.
  • YC137-resistant cells showed increased sensitivity to chemotherapy.

Conclusions:

  • YC137 demonstrates selective tumor cell killing potential.
  • The study identifies a novel mechanism linking HER2 to the Stat3-Bcl-2 pathway in breast cancer.
  • Understanding resistance mechanisms provides a basis for combination therapies and overcoming treatment failure.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...